Please wait while we load the requested 6-K report or click the link below:
https://last10k.com/sec-filings/report/1612042/000119312523068469/d435380d6k.htm
April 2024
March 2024
March 2024
February 2024
February 2024
January 2024
January 2024
January 2024
January 2024
January 2024
Please wait while we load the requested 6-K report or click the link below:
https://last10k.com/sec-filings/report/1612042/000119312523068469/d435380d6k.htm
Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Ascendis Pharma As.
Ascendis Pharma As's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Ticker: ASND
CIK: 1612042
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-23-068469
Submitted to the SEC: Mon Mar 13 2023 7:15:49 AM EST
Accepted by the SEC: Mon Mar 13 2023
Period: Monday, March 13, 2023
Industry: Pharmaceutical Preparations